Genmab - Phase 3 MAIA Study - Significant overall Survival
94218 Helge Larsen/PI-redaktør 12/6 2021 09:44
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress.
https://www.businesswire.com/news/home/20210612005027/en/%C2%A0Janssen-Announces-Results-from-Phase-3-MAIA-Study-Showing-Significant-Ov
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress.
https://www.businesswire.com/news/home/20210612005027/en/%C2%A0Janssen-Announces-Results-from-Phase-3-MAIA-Study-Showing-Significant-Ov
Det er outstanding resultater. En vidunderlig udvikling for patienterne som Genmab og Janssen har lykkedes med indtil videre indenfor knoglemarvskæft.
